Request Demo
Last update 27 Feb 2026
Drospirenone
Last update 27 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 1,2-Dihydrospirorenone, 6β,7β;15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, Dehydrospirorenone + [13] |
Action antagonists, agonists, inhibitors |
Mechanism AR antagonists(Androgen Receptor antagonists), MR antagonists(Mineralocorticoid receptor antagonists), PR agonists(Progesterone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (23 May 2019), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC24H30O3 |
InChIKeyMETQSPRSQINEEU-HXCATZOESA-N |
CAS Registry67392-87-4 |
Related
66
Clinical Trials associated with DrospirenoneNCT07293728
A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
NCT07340190
A Phase 1b, Open Label, 2-Part Study to Evaluate the Effect of Pelabresib (DAK539/CPI-0610) on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Patients With Advanced Malignancies
ChiCTR2500111618
Ovulation induction with oral contraception alone in biochemical to overt primary ovarian insufficiency: a pilot study.
100 Clinical Results associated with Drospirenone
Login to view more data
100 Translational Medicine associated with Drospirenone
Login to view more data
100 Patents (Medical) associated with Drospirenone
Login to view more data
1,074
Literatures (Medical) associated with Drospirenone01 Feb 2026JOURNAL OF HAZARDOUS MATERIALS
Drospirenone inhibits neurobehavioral activity in zebrafish larvae by modulating NMDA receptors
Article
Author: Chen, Manci ; Xi, Jinlei ; Yang, Zheqiong ; Yue, Jiang ; Wang, Xiaoxuan ; Wan, Qing ; Yu, Ting ; Wu, Wei ; Liu, Juan ; Li, Ke
Progestogens, primarily used in assisted reproduction and tocolytic therapy, have emerged as environmental pollutants due to their widespread use in medicine and aquaculture. Their release into various ecosystems has raised concerns about their potential neurodevelopmental effects. Drospirenone (DRS), an extensively used synthetic progestin, was identified in bioinformatic analysis as a potential disruptor of NMDA receptors (NMDARs), crucial for neuronal signaling. To investigate this, zebrafish embryos were exposed to DRS from 2 h post-fertilization (hpf) to 14 days post-fertilization (dpf). Behavioral assays revealed that DRS exposure impaired locomotor activity, reduced anxiety-like responses, and diminished social behaviors. Quantitative PCR and immunofluorescence staining showed that DRS disrupted the expression of several NMDAR subunits, suppressed apoptosis, and promoted neuronal proliferation in the embryonic brain. Co-exposure with NMDA, an NMDAR agonist, reversed the neurobehavioral deficits, normalized NMDARs expression, and restored apoptosis-proliferation balance. Molecular docking, DARTS assays, and downstream marker measurements indicated target engagement between DRS and the Grin1 and Grin2 subunits of NMDAR, suggesting that DRS may alter receptor conformation and function. In conclusion, DRS induces significant neurodevelopmental toxicity in zebrafish larvae, likely by suppressing NMDAR activity and disrupting neuronal apoptosis and proliferation. These findings highlight potential risks of DRS to aquatic life and human health.
01 Jan 2026ACTA NEUROPSYCHIATRICA
Differences in verbal memory, visuospatial ability and cognitive inhibition among young women using drospirenone and ethinyl oestradiol oral contraceptives versus naturally cycling controls
Article
Author: de la Torre-Luque, Alejandro ; Grassi, Daniela ; Diéguez-Risco, Teresa ; Sánchez-Giraldo, Laura ; Lagunas, Natalia
Abstract:
Objective::
This study aimed to investigate the differences on cognitive performance across four cognitive domains – verbal memory, language fluency, visuospatial ability and cognitive inhibition – between drospirenone and ethinyl oestradiol (DRSP/EE) users and naturally cycling women in the luteal phase (LP). The goal was to determine whether hormonal suppression associated with DRSP/EE use is linked to domain-specific cognitive alterations.
Methods::
A total of 48 young adult women were assessed: 23 using DRSP/EE (with pharmacologically suppressed endogenous hormonal levels) and 25 naturally cycling during the LP. Participants completed standardised neuropsychological tasks measuring verbal memory, language fluency, visuospatial ability and cognitive inhibition. Group comparisons analyses were conducted.
Results::
Significant group differences were observed in verbal memory, visuospatial ability and cognitive inhibition, while no significant group differences were found in language fluency. Women using DRSP/EE showed significantly lower performance in verbal memory (
U
= 165,
p
= 0.009,
r
= 0.38) and visuospatial ability (
U
= 155,
p
= 0.006,
r
= 0.40) tasks compared to naturally cycling women. In contrast, they demonstrated higher performance in cognitive inhibition, quantified by a significantly higher Stroop interference score (
t
(46) = 2.710,
p
= 0.009,
d
= 0.783).
Conclusion::
The present findings suggest that the use of DRSP/EE oral contraceptives is associated with differences across specific cognitive domains compared to naturally cycling women in the LP. The observed pattern – lower performance in hippocampus-related domains (verbal memory and visuospatial ability) paired with higher performance on a frontal-lobe-dependent task (cognitive inhibition) – is consistent with existing evidence suggesting that suppression of endogenous ovarian hormones may differentially influence cognitive functions. These behavioural associations underscore the need for further domain-specific research into the long-term cognitive implications of combined oral contraceptives.
01 Jan 2026Reproductive Medicine and Biology
Post Hoc Analysis of a Previous Study of Estetrol 15 mg/Drospirenone 3 mg Combination for Dysmenorrhea and Uterine Bleeding in Adenomyosis Patients
Article
Author: Koga, Eri ; Harada, Tasuku ; Sasahara, Ayaka ; Osuga, Yutaka ; Kobayashi, Takao ; Hirayama, Masashi ; Nogami, Masayoshi ; Takayanagi, Toshiaki
ABSTRACT:
Purpose:
To clarify the efficacy and safety of the estetrol 15 mg/drospirenone 3 mg combination among Japanese women with adenomyosis by post hoc analyses of a previous randomized clinical study.
Methods:
Post hoc analyses were performed using data from a 16‐week, multi‐center, randomized, double‐blinded, placebo‐controlled, parallel‐group study, followed by a 36‐week, open‐label extension study involving 162 Japanese women with dysmenorrhea. Participants received cyclic estetrol/drospirenone or placebo. The primary endpoint was the absolute change in total dysmenorrhea score from baseline to the end of the 16‐week double‐blinded period.
Results:
Among participants with adenomyosis, estetrol/drospirenone reduced the change from baseline of the total dysmenorrhea score at Week 16 by 2.5. The between‐treatment difference was estimated as −1.8 (two‐sided 95% confidence interval: −2.5 to −1.0), showing a significant difference from placebo (
p
< 0.001). Responder rate, as the proportion of participants who achieved a ≥ 2.0‐point reduction in total dysmenorrhea score from baseline, was 66.7% following 16‐week estetrol/drospirenone treatment, significantly greater than with placebo (20.0%;
p
< 0.001). Fewer safety concerns were reported with estetrol/drospirenone treatment, including the occurrence of venous thromboembolism.
Conclusions:
Estetrol/drospirenone ameliorates adenomyosis‐associated symptoms, offering safer treatment with potentially reduced thromboembolic risk.
Trial Registration:
jRCT registration number: jRCT2011210023
32
News (Medical) associated with Drospirenone12 Jun 2024
License out/inDrug Approval
12 Jun 2024
License out/inDrug Approval
100 Deals associated with Drospirenone
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D03917 | Drospirenone |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Contraception | United States | 23 May 2019 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Endometriosis | Phase 3 | Slovakia | - | 24 Jul 2021 |
| Dysmenorrhea | Phase 2 | Japan | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
| - | - | zrduxaxtki(whbfeqvdam) = Clinical results have reached the endpoint kwvedpyiai (afnjxluvis ) | Positive | 13 Nov 2024 | |||
Phase 4 | 30 | mnavhlqzpy = vttvckgcas iguvaqiexk (fnrhdfxhyu, dxzbvustgk - gtvckehfrl) View more | - | 19 Apr 2024 | |||
mnavhlqzpy = uhsozquxly iguvaqiexk (fnrhdfxhyu, ydehecmicj - jbyqdswtwi) View more | |||||||
Not Applicable | - | (Nonobese participants) | xgfjrlqgui(huvlscoxyz) = rlcolqeygl ejcbmmdmsu (gfhyftbsbb, 1.3 - 5.8) | Positive | 01 Dec 2023 | ||
(Obese participants) | xgfjrlqgui(huvlscoxyz) = etqbfvhcns ejcbmmdmsu (gfhyftbsbb, 0.8 - 7.3) | ||||||
Phase 3 | - | 48 | vjvomgvyob(edduveynwd) = No ovulations occurred during treatment bfnelonfhf (kfwygpmvkm ) | - | 01 Oct 2010 | ||
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free